RX-208

N/A

Report date: 2025/10/30 14:38:51
NME

Base Information

Drug NameRX-208
Drug Alias NameRX-208HLX-208
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionB-raf V600E inhibitors
TargetsB-raf V600E
Therapy Area/IndicationsSolid tumoursErdheim-Chester DiseaseHistiocytosis, Langerhans-Cell +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSuzhou Neupharma Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSuzhou Neupharma Co LtdShanghai Henlius Biotech Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursErdheim-Chester DiseaseHistiocytosis, Langerhans-Cell +[11] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A